AI-assisted drug discovery (AIDD) is one of the most active frontiers at the intersection of synthetic biology and AI. Traditional drug discovery (target identification → lead compound → structural optimization → preclinical → clinical) averages 12–15 years and over $1 billion in cost, with failure rates above 90% (approximately 90% of compounds entering Phase I clinical trials never reach market). AI aims to accelerate each stage, reduce failure rates, and compress R&D costs.
## AlphaFold: The Structure Prediction Revolution
**AlphaFold2** (DeepMind, 2020) is among the most important AI breakthroughs in life sciences in the past decade — predicting protein 3D structures at ~90% atomic-level accuracy, solving the “protein folding problem” (predicting 3D structure from amino acid sequence — a 50-year unsolved challenge). DeepMind open-sourced structure predictions for all ~200 million known human proteins for global researchers. **AlphaFold3** (2024) extended to complex structure prediction for small molecules, DNA, RNA, and proteins combined — directly valuable for drug-target interaction prediction.
## Core AI Drug Discovery Applications
**Target identification and validation**: machine learning analysis of large-scale omics data (genomics, transcriptomics, proteomics) to identify disease-related new targets and prioritize them.
**Virtual screening**: deep learning models (DiffDock and other docking tools) predict small molecule-target binding affinity, rapidly screening millions of compound libraries for potential candidates — partially replacing traditional high-throughput screening (HTS).
**De novo molecular design**: generative AI (diffusion models, reinforcement learning) directly designs new molecular structures with target properties (high affinity, low toxicity, good druggability) without being limited to existing compound libraries.
**ADMET prediction**: predicting compound Absorption, Distribution, Metabolism, Excretion, and Toxicity properties to filter poor druggability candidates before experimental testing.
## Representative Companies and Cases
**Insilico Medicine** (Hong Kong/Beijing): the world’s first company advancing an AI-discovered drug candidate (INS018_055 for pulmonary fibrosis) to Phase II clinical trials.
**Recursion Pharmaceuticals**: uses cell imaging + AI to identify phenotypic changes, building large-scale biology-phenotype databases.
See [Synthetic Biology Overview](https://sunqi.org/synthetic-biology-overview-en/) and [AlphaFold database](https://alphafold.ebi.ac.uk/).
